Tags

Type your tag names separated by a space and hit enter

Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats.
Eur J Pharmacol. 2005 Dec 28; 528(1-3):43-51.EJ

Abstract

We established a rat chronic alveolar hypoxia in vivo model to evaluate the efficacy against hypoxic pulmonary hypertension of a new angiotensin II-receptor I blocker, olmesartan medoxomil. Three groups of rats were established: rats exposed for 2-6 weeks to 10% oxygen atmosphere in a normobaric chamber; hypoxic rats treated with olmesartan medoxomil oral administration (5 mg/day) every day; and control rats fed in a normoxic condition. After hypoxia treatment, the presence, etiology and severity of pulmonary hypertension, was echocardiographically evaluated, and expressions of brain natriuretic peptide (BNP), transforming growth factor (TGF-beta) and endothelin-1 genes measured by both immunohistochemical assay and real-time polymerase chain reaction. Olmesartan medoxomil significantly reduced the induction of hypoxic cor pulmonale not only on echocardiographical observations but also in BNP, TGF-beta and endothelin gene expressions in molecular studies. However, systolic blood pressure was independent of olmesartan medoxomil. The present study clearly indicates that the angiotensin II-type I-receptor blocker olmesartan medoxomil has significant efficacy for hypoxic cor pulmonale.

Authors+Show Affiliations

Department of Cardiology and Pneumology, Dokkyo University School of Medicine, Mibu, Tochigi, Japan. takanaka@dokkyomed.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16336959

Citation

Nakamoto, Takaaki, et al. "Effects of Olmesartan Medoxomil as an Angiotensin II-receptor Blocker in Chronic Hypoxic Rats." European Journal of Pharmacology, vol. 528, no. 1-3, 2005, pp. 43-51.
Nakamoto T, Harasawa H, Akimoto K, et al. Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats. Eur J Pharmacol. 2005;528(1-3):43-51.
Nakamoto, T., Harasawa, H., Akimoto, K., Hirata, H., Kaneko, H., Kaneko, N., & Sorimachi, K. (2005). Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats. European Journal of Pharmacology, 528(1-3), 43-51.
Nakamoto T, et al. Effects of Olmesartan Medoxomil as an Angiotensin II-receptor Blocker in Chronic Hypoxic Rats. Eur J Pharmacol. 2005 Dec 28;528(1-3):43-51. PubMed PMID: 16336959.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats. AU - Nakamoto,Takaaki, AU - Harasawa,Hiroshi, AU - Akimoto,Kazumi, AU - Hirata,Hisato, AU - Kaneko,Hiromichi, AU - Kaneko,Noboru, AU - Sorimachi,Kenji, Y1 - 2005/12/05/ PY - 2005/06/27/received PY - 2005/10/18/revised PY - 2005/10/25/accepted PY - 2005/12/13/pubmed PY - 2006/3/10/medline PY - 2005/12/13/entrez SP - 43 EP - 51 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 528 IS - 1-3 N2 - We established a rat chronic alveolar hypoxia in vivo model to evaluate the efficacy against hypoxic pulmonary hypertension of a new angiotensin II-receptor I blocker, olmesartan medoxomil. Three groups of rats were established: rats exposed for 2-6 weeks to 10% oxygen atmosphere in a normobaric chamber; hypoxic rats treated with olmesartan medoxomil oral administration (5 mg/day) every day; and control rats fed in a normoxic condition. After hypoxia treatment, the presence, etiology and severity of pulmonary hypertension, was echocardiographically evaluated, and expressions of brain natriuretic peptide (BNP), transforming growth factor (TGF-beta) and endothelin-1 genes measured by both immunohistochemical assay and real-time polymerase chain reaction. Olmesartan medoxomil significantly reduced the induction of hypoxic cor pulmonale not only on echocardiographical observations but also in BNP, TGF-beta and endothelin gene expressions in molecular studies. However, systolic blood pressure was independent of olmesartan medoxomil. The present study clearly indicates that the angiotensin II-type I-receptor blocker olmesartan medoxomil has significant efficacy for hypoxic cor pulmonale. SN - 0014-2999 UR - https://www.unboundmedicine.com/medline/citation/16336959/Effects_of_olmesartan_medoxomil_as_an_angiotensin_II_receptor_blocker_in_chronic_hypoxic_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(05)01099-X DB - PRIME DP - Unbound Medicine ER -